&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-03-11, 22:10

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-12-06, 20:05

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mul

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-12-13, 00:37

FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research

Notified -

Popular Posts